Acute myocardial infarction with cardiogenic shock in a young physically active physician concurrently using the anabolic steroid sustanon: A case report

Alrabadi,Nasr; Jarrah,Mohamad Ismail; Alzoubi,Karem Hasan

doi:10.3892/br.2020.1321

Acute myocardial infarction with cardiogenic shock in a young physically active physician concurrently using the anabolic steroid sustanon: A case report

Authors:
- Nasr Alrabadi
- Mohamad Ismail Jarrah
- Karem Hasan Alzoubi
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan, Department of Internal Medicine, Interventional Cardiology Division, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan, Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan
Published online on: June 26, 2020 https://doi.org/10.3892/br.2020.1321
Article Number: 14

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between ischemic heart disease (IHD) and the concurrent use of anabolic androgenic steroids (AASs) is underestimated in clinical settings. The tendency of patients to not disclose AASs use may explain this underestimation. In the present case report, the clinical case of a 26‑year‑old physically active male, who was a physician, without any classical coronary risk factors, who presented with chest pain that was misdiagnosed by the peripheral care unit as skeletal muscle pain is described. Later, the patient was brought to our central hospital (King Abdullah University Hospital) suffering from a massive acute myocardial infarction with marked ECG changes and cardiogenic shock. Following stabilization of his condition, a detailed history of the patient was taken, during which the patient admitted that he was a chronic user of the anabolic steroid sustanon (250 mg, once/week for 6 months) and amino acid supplements (whey protein isolate, 6 tabs every day for 1 year). Specific cardiac markers were increased and the patient exhibited dynamic ischemic changes in his electrocardiogram. Notably, the coronary angiogram of the patient demonstrated ostial occlusion of the left anterior descending artery, which was associated with mid‑right coronary artery embolic obstruction. Other than the anabolic steroids and protein supplementation use, the patient history, examination and lab evaluation were normal. During follow up, the patient continued to suffer heart failure with low ejection fraction. In addition, he developed apical thrombus 2 months after primary admission. The patient developed tachycardia in spite of optimal medical treatment and finally received an implantable cardioverter defibrillator. Physicians should always be aware of the possibility of AASs use in young physically active patients. IHD should always be suspected and investigated with typical chest pain in healthy young patients, even if regular risk factors are not present. Medical professionals should not be excluded as potential AASs users/abusers.

View Figures

View References

1	Santos RP, Pereira A, Guedes H, Lourenço C, Azevedo J and Pinto P: Anabolic drugs and myocardial infarction-a clinical case report. Arq Bras Cardiol. 105:316–319. 2015.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
2	Stergiopoulos K, Brennan JJ, Mathews R, Setaro JF and Kort S: Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vasc Health Risk Manag. 4:1475–1480. 2008.PubMed/NCBI View Article : Google Scholar
3	Luijkx T, Velthuis BK, Backx FJ, Buckens CF, Prakken NH, Rienks R, Mali WP and Cramer MJ: Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol. 167:664–668. 2013.PubMed/NCBI View Article : Google Scholar
4	Kersey RD, Elliot DL, Goldberg L, Kanayama G, Leone JE, Pavlovich M and Pope HG Jr: National Athletic Trainers' Association. National athletic trainers' association position statement: Anabolic-androgenic steroids. J Athl Train. 47:567–588. 2012.PubMed/NCBI View Article : Google Scholar
5	Christou GA, Christou KA, Nikas DN and Goudevenos JA: Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. Eur J Prev Cardiol. 23:1785–1796. 2016.PubMed/NCBI View Article : Google Scholar
6	Peoples K, Kobe D, Campana C and Simon E: Hyperhomocysteinemia-induced myocardial infarction in a young male using anabolic steroids. Am J Emerg Med. 32:948.e1–2. 2014.PubMed/NCBI View Article : Google Scholar
7	Ilhan E, Demirci D, Güvenç TS and Calık AN: Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. Turk Kardiyol Dern Ars. 38:275–278. 2010.PubMed/NCBI
8	Wysoczanski M, Rachko M and Bergmann SR: Acute myocardial infarction in a young man using anabolic steroids. Angiology. 59:376–378. 2008.PubMed/NCBI View Article : Google Scholar
9	Hartgens F, Rietjens G, Keizer HA, Kuipers H and Wolffenbuttel BH: Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 38:253–259. 2004.PubMed/NCBI View Article : Google Scholar
10	Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G and Karch SB: Sudden cardiac death during anabolic steroid abuse: Morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med. 121:48–53. 2007.PubMed/NCBI View Article : Google Scholar
11	Kennedy MC, Corrigan AB and Pilbeam ST: Myocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids. Aust N Z J Med. 23(713)1993.PubMed/NCBI View Article : Google Scholar
12	Lyngberg KK: Myocardial infarction and death of a body builder after using anabolic steroids. Ugeskr Laeger. 153:587–588. 1991.PubMed/NCBI(In Danish).
13	Pilo R, Aharony D and Raz A: Testosterone potentiation of ionophore and ADP induced platelet aggregation: Relationship to arachidonic acid metabolism. Thromb Haemost. 46:538–542. 1981.PubMed/NCBI
14	Kokkonen L, Anttonen O, Penttilä O and Voutilainen S: Protein C deficiency and use of anabolic steroids behind the myocardial infarction in a young man. Duodecim. 117:2279–2281. 2001.PubMed/NCBI(In Finnish).
15	Buttner A, Sachs H, Mall G, Tutsch-Bauer E and Weis S: Progressive idiopathic bilateral striato-pallido-dentate calcinosis (Fahr's disease) in a person with anabolic steroid abuse. Leg Med (Tokyo). 3:114–118. 2001.PubMed/NCBI View Article : Google Scholar
16	Sonmez E, Turkdogan KA, Yilmaz C, Kucukbuzcu S, Ozkan A and Sogutt O: Chronic anabolic androgenic steroid usage associated with acute coronary syndrome in bodybuilder. Turk J Emerg Med. 16:35–37. 2016.PubMed/NCBI View Article : Google Scholar
17	Skogastierna C, Hotzen M, Rane A and Ekström L: A supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. Eur J Prev Cardiol. 21:1049–1054. 2014.PubMed/NCBI View Article : Google Scholar
18	Tischer KH, Heyny-von Haussen R, Mall G and Doenecke P: Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids. Z Kardiol. 92:326–331. 2003.PubMed/NCBI View Article : Google Scholar : (In German).
19	Phillis BD, Abeywardena MY, Adams MJ, Kennedy JA and Irvine RJ: Nandrolone potentiates arrhythmogenic effects of cardiac ischemia in the rat. Toxicol Sci. 99:605–611. 2007.PubMed/NCBI View Article : Google Scholar
20	Sculthorpe N, Grace F, Jones P and Davies B: Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use. Cardiovasc Toxicol. 10:239–243. 2010.PubMed/NCBI View Article : Google Scholar
21	Maior AS, Carvalho AR, Marques-Neto SR, Menezes P, Soares PP and Nascimento JH: Cardiac autonomic dysfunction in anabolic steroid users. Scand J Med Sci Sports. 23:548–555. 2013.PubMed/NCBI View Article : Google Scholar
22	Kasikcioglu E, Oflaz H, Umman B and Bugra Z: Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol. 134:123–125. 2009.PubMed/NCBI View Article : Google Scholar
23	Frati P, Busardò FP, Cipolloni L, Dominicis ED and Fineschi V: Anabolic androgenic steroid (AAS) related deaths: Autoptic, histopathological and toxicological findings. Curr Neuropharmacol. 13:146–159. 2015.PubMed/NCBI View Article : Google Scholar
24	Gheshlaghi F, Piri-Ardakani MR, Masoumi GR, Behjati M and Paydar P: Cardiovascular manifestations of anabolic steroids in association with demographic variables in body building athletes. J Res Med Sci. 20:165–168. 2015.PubMed/NCBI